ALXO ALX ONCOLOGY HOLDINGS INC Insider Trading

Director Corey Goodman buys 3,184,713 shares of ALXO for $5.0M at $1.57 amid unprofitable biotech operations.

Director Corey Goodman purchased 3,184,713 shares at $1.57 on 2026-02-02, increasing his holdings from 5,268,325 to 8,453,038 shares (+60.5%). The transaction value of $4,999,999.41 represents a substantial personal commitment in an unprofitable biotech company operating at a $-22.1M net loss with only $527.0K in latest quarterly revenue. The stock has appreciated 79.5% over the past 30 days and currently trades at $2.01, up 28% from the $1.57 purchase price, suggesting the market has responded positively post-transaction. This large director accumulation in a cash-burn-stage company with minimal revenue warrants scrutiny regarding the risk profile and capital allocation strategy.

ALXO CEO Jason Lettmann bought 92,233 shares (avg $1.08) on 2025-09-16/17; holdings +43.3% to 305.1K shares.

CEO Jason Lettmann purchased 92,233 shares across two separate transactions totaling $99,352.24 at an average price of $1.08, increasing his holdings by 43.3% to 305,121 shares. The company is unprofitable with net income of $-25,949,000.00 over its most recent full fiscal year and reported only $527,000.00 in revenue in the latest quarter, creating a notable mismatch between the scale of insider accumulation and the company's financial profile. Lettmann's prior buy at ALXO on 2024-03-14 returned -24.6% over 90 days, and his cross-ticker track record shows a 0.00% win rate across 90-day periods, suggesting a pattern of poorly-timed buys. The current stock price of $1.09 is -50.9% from its 52-week high and the recent 30-day surge of +22.5% immediately preceding this purchase may warrant scrutiny into the motivations and timing of this substantial equity commitment.

CFO Shantharam Harish bought 75,000 shares (75.0K) of ALXO at $0.78; stock -68.7% from 52-week high in unprofitable biotech.

Shantharam Harish, Chief Financial Officer, purchased 75,000 shares at $0.78 on 2025-08-18 for a total value of $58,402.50, establishing an initial position in the company. This purchase occurs in a severely distressed context: ALXO trades at $0.83, down 68.7% from its 52-week high of $2.65, while the company reported a net loss of $-25,949,000 against quarterly revenue of only $527,000.00. The stock has recovered +72.9% over the prior 30 days and +73.3% over 90 days, suggesting ALXO has experienced a sharp recent rally from depressed levels. A CFO's initial establishment of a material position (75,000 shares) in a capital-constrained, unprofitable oncology company warrants investor attention to the underlying clinical or strategic developments driving this transaction, and whether recent price recovery reflects genuine business momentum or sector-wide rebound.

Director Hemrajani Rekha buys 30,000 ALXO shares at $1.55; holdings surge 1000.0% to 33,000 shares amid -91.1% 52-week drawdown

Director Hemrajani Rekha purchased 30,000 shares of ALX Oncology at $1.55 on 2024-12-02, increasing her holdings from 3,000 to 33,000 shares—a net increase of 1000.0% on her prior position. The stock trades at $1.56 currently, down -91.1% from its 52-week high of $17.56, and the company remains unprofitable with net income of $-30.7M against quarterly revenue of $527.0K. This represents a substantial proportional increase in director ownership at a depressed absolute price level, though the timing occurs within a modest recent 30-day recovery of +4.7% after a steeper 90-day decline of -21.6%. The transaction signals meaningful insider capital deployment in a distressed biotech; investors should monitor whether this reflects board-level conviction in recovery prospects or simply opportunistic accumulation at historic lows given the company's negative earnings trajectory.

CFO Peter Garcia buys 12,000 ALXO shares at $8.53; stock now $7.38, down 58.0% from 52-week high.

Peter S. Garcia, CFO of ALX Oncology, purchased 12,000 shares at $8.53 on 2024-06-13, increasing his holdings from 110,348 to 122,348 shares. The acquisition occurred when the stock was already in substantial decline—down 48.1% over the prior 30 days and 58.0% below its 52-week high of $17.56. The company is unprofitable, with a net loss of $35,581,000 in the latest full fiscal year and only $527,000 in recent quarterly revenue, creating a challenging backdrop. The timing of this purchase—after sharp recent losses and amid fundamental weakness—presents a contrarian signal that warrants attention to management's internal perspective on the company's trajectory.